View in EDS HTML Full Text PDF Full Text

Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform.

Saved in:
Bibliographic Details
Title: Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform.
Authors: Kovesdy CP; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.; Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee, USA., Ebert N; Institute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany., Vizcaya D; Medical, Pharmaceuticals, Integrated Evidence Generation and Business Insights, Bayer Hispania, S.L., Sant Joan Despí, Spain., Walsh M; The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.; Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada., Kosiborod MN; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA., Layton JB; RTI Health Solutions, Durham, North Carolina, USA., Ziemiecki R; RTI Health Solutions, Durham, North Carolina, USA., Johannes CB; RTI Health Solutions, Waltham, Massachusetts, USA., Pladevall-Vila M; RTI Health Solutions, Durham, North Carolina, USA.; The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA., Gee PO; Founder and CEHD, iAdvocate, Inc, North Chesterfield, Virginia, USA., Jefferson N; Kidney Precision Medicine Project Community Engagement Committee, Dallas, Texas, USA., Chicoye A; Sciences Po Paris, Paris, France., Lopes M; AMC Health, New York, New York, USA., Thapa BB; OM1, Inc, Boston, Massachusetts, USA., Curhan G; OM1, Inc, Boston, Massachusetts, USA., Rangel L; OM1, Inc, Boston, Massachusetts, USA., Bhartia M; OM1, Inc, Boston, Massachusetts, USA., Liu F; Medical Affairs and Pharmacovigilance, Pharmaceuticals, OS Operations 2, IEG Study Operations, Bayer AG, Wuppertal, Germany., Farjat AE; Pharmaceuticals, Statistics and Data Insights, Bayer plc, Reading, UK., Oberprieler NG; Pharmaceuticals, MA & PV, Integrated Evidence Generation and Business Innovation, Bayer AS, Oslo, Norway.
Source: Nephron [Nephron] 2025; Vol. 149 (7), pp. 371-383. Date of Electronic Publication: 2025 Feb 27.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Karger Country of Publication: Switzerland NLM ID: 0331777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2235-3186 (Electronic) Linking ISSN: 16608151 NLM ISO Abbreviation: Nephron Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40015260
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kovesdy+CP%22">Kovesdy CP</searchLink>; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.; Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Ebert+N%22">Ebert N</searchLink>; Institute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Vizcaya+D%22">Vizcaya D</searchLink>; Medical, Pharmaceuticals, Integrated Evidence Generation and Business Insights, Bayer Hispania, S.L., Sant Joan Despí, Spain.<br /><searchLink fieldCode="AU" term="%22Walsh+M%22">Walsh M</searchLink>; The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.; Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Kosiborod+MN%22">Kosiborod MN</searchLink>; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.<br /><searchLink fieldCode="AU" term="%22Layton+JB%22">Layton JB</searchLink>; RTI Health Solutions, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Ziemiecki+R%22">Ziemiecki R</searchLink>; RTI Health Solutions, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Johannes+CB%22">Johannes CB</searchLink>; RTI Health Solutions, Waltham, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Pladevall-Vila+M%22">Pladevall-Vila M</searchLink>; RTI Health Solutions, Durham, North Carolina, USA.; The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA.<br /><searchLink fieldCode="AU" term="%22Gee+PO%22">Gee PO</searchLink>; Founder and CEHD, iAdvocate, Inc, North Chesterfield, Virginia, USA.<br /><searchLink fieldCode="AU" term="%22Jefferson+N%22">Jefferson N</searchLink>; Kidney Precision Medicine Project Community Engagement Committee, Dallas, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Chicoye+A%22">Chicoye A</searchLink>; Sciences Po Paris, Paris, France.<br /><searchLink fieldCode="AU" term="%22Lopes+M%22">Lopes M</searchLink>; AMC Health, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Thapa+BB%22">Thapa BB</searchLink>; OM1, Inc, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Curhan+G%22">Curhan G</searchLink>; OM1, Inc, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Rangel+L%22">Rangel L</searchLink>; OM1, Inc, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bhartia+M%22">Bhartia M</searchLink>; OM1, Inc, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Liu+F%22">Liu F</searchLink>; Medical Affairs and Pharmacovigilance, Pharmaceuticals, OS Operations 2, IEG Study Operations, Bayer AG, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Farjat+AE%22">Farjat AE</searchLink>; Pharmaceuticals, Statistics and Data Insights, Bayer plc, Reading, UK.<br /><searchLink fieldCode="AU" term="%22Oberprieler+NG%22">Oberprieler NG</searchLink>; Pharmaceuticals, MA & PV, Integrated Evidence Generation and Business Innovation, Bayer AS, Oslo, Norway.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220331777%22">Nephron</searchLink> [Nephron] 2025; Vol. 149 (7), pp. 371-383. <i>Date of Electronic Publication: </i>2025 Feb 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Karger%22">Karger </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>0331777 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2235-3186 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216608151%22">16608151 </searchLink><i>NLM ISO Abbreviation: </i>Nephron <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40015260
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1159/000543923
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 371
    Titles:
      – TitleFull: Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kovesdy CP
      – PersonEntity:
          Name:
            NameFull: Ebert N
      – PersonEntity:
          Name:
            NameFull: Vizcaya D
      – PersonEntity:
          Name:
            NameFull: Walsh M
      – PersonEntity:
          Name:
            NameFull: Kosiborod MN
      – PersonEntity:
          Name:
            NameFull: Layton JB
      – PersonEntity:
          Name:
            NameFull: Ziemiecki R
      – PersonEntity:
          Name:
            NameFull: Johannes CB
      – PersonEntity:
          Name:
            NameFull: Pladevall-Vila M
      – PersonEntity:
          Name:
            NameFull: Gee PO
      – PersonEntity:
          Name:
            NameFull: Jefferson N
      – PersonEntity:
          Name:
            NameFull: Chicoye A
      – PersonEntity:
          Name:
            NameFull: Lopes M
      – PersonEntity:
          Name:
            NameFull: Thapa BB
      – PersonEntity:
          Name:
            NameFull: Curhan G
      – PersonEntity:
          Name:
            NameFull: Rangel L
      – PersonEntity:
          Name:
            NameFull: Bhartia M
      – PersonEntity:
          Name:
            NameFull: Liu F
      – PersonEntity:
          Name:
            NameFull: Farjat AE
      – PersonEntity:
          Name:
            NameFull: Oberprieler NG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2235-3186
          Numbering:
            – Type: volume
              Value: 149
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Nephron
              Type: main
ResultId 1